151 related articles for article (PubMed ID: 38184429)
1. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease.
Kenney-Jung D; Korlimarla A; Spiridigliozzi GA; Wiggins W; Malinzak M; Nichting G; Jung SH; Sun A; Wang RY; Al Shamsi A; Phornphutkul C; Owens J; Provenzale JM; Kishnani PS
Mol Genet Metab; 2024 Feb; 141(2):108119. PubMed ID: 38184429
[TBL] [Abstract][Full Text] [Related]
2. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy.
Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B
Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078
[TBL] [Abstract][Full Text] [Related]
3. Evaluating brain white matter hyperintensity, IQ scores, and plasma neurofilament light chain concentration in early-treated patients with infantile-onset Pompe disease.
Hsu YK; Chien YH; Shinn-Forng Peng S; Hwu WL; Lee WT; Lee NC; Po-Yu Huang E; Weng WC
Genet Med; 2023 Jan; 25(1):27-36. PubMed ID: 36399131
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up.
Spiridigliozzi GA; Keeling LA; Stefanescu M; Li C; Austin S; Kishnani PS
Mol Genet Metab; 2017 Jun; 121(2):127-137. PubMed ID: 28495044
[TBL] [Abstract][Full Text] [Related]
5. Novel approaches to quantify CNS involvement in children with Pompe disease.
Korlimarla A; Spiridigliozzi GA; Crisp K; Herbert M; Chen S; Malinzak M; Stefanescu M; Austin SL; Cope H; Zimmerman K; Jones H; Provenzale JM; Kishnani PS
Neurology; 2020 Aug; 95(6):e718-e732. PubMed ID: 32518148
[TBL] [Abstract][Full Text] [Related]
6. Expert Group Consensus on early diagnosis and management of infantile-onset pompe disease in the Gulf Region.
Al-Hassnan Z; Hashmi NA; Makhseed N; Omran TB; Al Jasmi F; Teneiji AA
Orphanet J Rare Dis; 2022 Oct; 17(1):388. PubMed ID: 36303251
[TBL] [Abstract][Full Text] [Related]
7. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.
Avula S; Nguyen TM; Marble M; Lilje C
Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734
[TBL] [Abstract][Full Text] [Related]
8. Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.
Hsueh CY; Huang CY; Yang CF; Chang CC; Lin WS; Cheng HL; Wu SL; Cheng YF; Niu DM
Orphanet J Rare Dis; 2021 Aug; 16(1):348. PubMed ID: 34353347
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and genotypes in the ADVANCE baseline data set, a comprehensive cohort of US children and adolescents with Pompe disease.
Kishnani PS; Gibson JB; Gambello MJ; Hillman R; Stockton DW; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Day JW; Wang RY; Goldstein JL; An Haack K; Sparks SE; Zhao Y; Hahn SH;
Genet Med; 2019 Nov; 21(11):2543-2551. PubMed ID: 31086307
[TBL] [Abstract][Full Text] [Related]
11. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.
Ebbink BJ; Aarsen FK; van Gelder CM; van den Hout JM; Weisglas-Kuperus N; Jaeken J; Lequin MH; Arts WF; van der Ploeg AT
Neurology; 2012 May; 78(19):1512-8. PubMed ID: 22539577
[TBL] [Abstract][Full Text] [Related]
12. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
[TBL] [Abstract][Full Text] [Related]
13. White matter lesions in treated late onset Pompe disease are not different to matched controls.
Schneider I; Hensel O; Zierz S
Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
[TBL] [Abstract][Full Text] [Related]
14. Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry.
Kishnani PS; Kronn D; Suwazono S; Broomfield A; Llerena J; Al-Hassnan ZN; Batista JL; Wilson KM; Periquet M; Daba N; Hahn A; Chien YH
Orphanet J Rare Dis; 2023 Dec; 18(1):381. PubMed ID: 38057861
[TBL] [Abstract][Full Text] [Related]
15. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.
McIntosh PT; Hobson-Webb LD; Kazi ZB; Prater SN; Banugaria SG; Austin S; Wang R; Enterline DS; Frush DP; Kishnani PS
Mol Genet Metab; 2018 Feb; 123(2):85-91. PubMed ID: 29050825
[TBL] [Abstract][Full Text] [Related]
16. The earliest enzyme replacement for infantile-onset Pompe disease in Japan.
Tocan V; Mushimoto Y; Kojima-Ishii K; Matsuda A; Toda N; Toyomura D; Hirata Y; Sanefuji M; Sawada T; Sakai Y; Nakamura K; Ohga S
Pediatr Int; 2022 Jan; 64(1):e15286. PubMed ID: 36074069
[TBL] [Abstract][Full Text] [Related]
17. Airway abnormalities in very early treated infantile-onset Pompe disease: A large-scale survey by flexible bronchoscopy.
Yang CF; Niu DM; Tai SK; Wang TH; Su HT; Huang LY; Soong WJ
Am J Med Genet A; 2020 Apr; 182(4):721-729. PubMed ID: 31953985
[TBL] [Abstract][Full Text] [Related]
18. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of 64 children with classical infantile-onset Pompe disease since 2004: A French real-life observational study.
Tardieu M; Cudejko C; Cano A; Hoebeke C; Bernoux D; Goetz V; Pichard S; Brassier A; Schiff M; Feillet F; Rollier P; Mention K; Dobbelaere D; Fouilhoux A; Espil-Taris C; Eyer D; Huet F; Walther-Louvier U; Barth M; Chevret L; Kuster A; Lefranc J; Neveu J; Pitelet G; Ropars J; Rivier F; Roubertie A; Touati G; Vanhulle C; Tardieu E; Caillaud C; Froissart R; Champeaux M; Labarthe F; Chabrol B
Eur J Neurol; 2023 Sep; 30(9):2828-2837. PubMed ID: 37235686
[TBL] [Abstract][Full Text] [Related]
20. Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain.
Ebbink BJ; Poelman E; Aarsen FK; Plug I; Régal L; Muentjes C; van der Beek NAME; Lequin MH; van der Ploeg AT; van den Hout JMP
Dev Med Child Neurol; 2018 Jun; 60(6):579-586. PubMed ID: 29573408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
